losartan-potassium and Hematuria

Heavy chain deposition disease (HCDD) is a comparatively recently described entity characterized by glomerular and tubular basement membrane deposition of monoclonal heavy chains without associated light chains. To our knowledge, review of the literature shows only 24 previously reported cases of HCDD with unequivocal evidence of monoclonal heavy chain deposition in the kidney using immunofluorescence microscopic and electron microscopic studies. The predominant heavy chain subtype was γ. There has been a single case of μ HCDD and 2 previously reported cases of α HCDD. In this report, we describe 3 additional cases of α HCDD, all with a crescentic pattern of injury and one of which was associated with cutis laxa. We compare their clinicopathologic features with all previously reported cases of HCDD.

Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cutis Laxa; Dexamethasone; Diabetic Nephropathies; Erythropoietin; Fatal Outcome; Female; Heavy Chain Disease; Hematuria; Humans; Hypertension, Renal; Immunoglobulin alpha-Chains; Immunoglobulin gamma-Chains; Immunoglobulin mu-Chains; Kidney Glomerulus; Male; Multiple Myeloma; Paraproteinemias; Proteinuria; Pyrazines; Thalidomide; Urticaria; Vasculitis, Leukocytoclastic, Cutaneous

Topics: Erythropoietin; Hematuria; Humans; Kidney Diseases; Low Back Pain; Nephrectomy; Renal Dialysis; Syndrome

The diverse systemic effects associated with malignant renal tumours are described. It is emphasized that their recognition is essential for the early diagnosis of the tumour and that many of these effects may be overlooked unless the clinician is alert to their significance. Many of these early diagnostic clues also have a prognostic value.Although the basic management of a patient with a renal tumour continues to be a nephrectomy, the importance of tumour staging in relation to radical surgery is emphasized. Adjuvant therapy by radiotherapy, drugs, or immunotherapy is described and evaluated.

Topics: Adenocarcinoma; Alkaline Phosphatase; Alpha-Globulins; Amyloidosis; Anemia; Blood Sedimentation; Cachexia; Erythropoietin; Feeding and Eating Disorders; Fever of Unknown Origin; Hematuria; Hemoglobinometry; Humans; Immunotherapy; Kidney Neoplasms; Liver Function Tests; Medroxyprogesterone; Nephrectomy; Parathyroid Hormone; Prognosis; Renin; Urography

Topics: Acute Kidney Injury; Adult; Blood Component Transfusion; Bone Marrow; Cell Lineage; Combined Modality Therapy; Darbepoetin alfa; Erythropoietin; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematuria; Humans; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphohistiocytosis, Hemophagocytic; Male; Mycophenolic Acid; Myelodysplastic Syndromes; Pancytopenia; Pericarditis; Prednisone; Proteinuria; Recombinant Proteins

Erythropoietin, a glycoprotein growth hormone that is produced primarily in the kidneys, promotes mitosis and survival of erythroid progenitors. The recent synthesis of the human form of the hormone by recombinant technology has provided a new therapeutic option, which is being used in both human and veterinary medicine for treatment of various anemias. A mature male rough-toothed dolphin, Steno bredanensis, was treated with human recombinant erythropoietin in an attempt to resolve a nonregenerative anemia. Two i.m. injections 48 hr apart were associated with an almost immediate increase in circulating immature reticulocytes, total reticulocytes, and nucleated erythrocytes. Over the next several weeks, the hematocrit, hemoglobin, and erythrocyte counts returned to normal, and the animal was subsequently released back into the wild. Endogenous erythropoietin concentrations were determined for this animal as well as three other conspecifics by an enzyme-linked immunosorbent assay for human erythropoietin. These measurements showed circulating erythropoietin concentrations (5-20+ mU/ml) similar to those of most other mammals. This study suggests that human recombinant erythropoietin can be safely and effectively used in this species and may have applicability to other cetacean species for the treatment of nonregenerative anemia. Caution should be exercised during long-term use because production of antibodies to human recombinant and endogenous erythropoietin may lead to potentially serious side effects.

Topics: Anemia; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Dolphins; Enzyme-Linked Immunosorbent Assay; Erythropoietin; Flow Cytometry; Gentamicins; Glomerulonephritis; Hematocrit; Hematuria; Hemoglobins; Male; Proteinuria; Ranitidine; Recombinant Proteins; Reference Values; Sucralfate

Topics: Age Factors; Angiography; Aortography; Blood Sedimentation; Child; Child, Preschool; Erythropoietin; Gastrointestinal Diseases; Hematuria; Humans; Infant; Iron; Kidney Neoplasms; Physical Examination; Prognosis; Radiography, Abdominal; Radioisotopes; Tomography, X-Ray; Ultrasonography; Urography; Vena Cava, Inferior; Wilms Tumor